Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph M Connors

Showing results (161-170 of 302) with videos related to

Pageof 31
Sort By:
Plos One|October 8, 2013
Non-Hodgkin lymphoma risk and variants in genes controlling lymphocyte developmentJohanna M Schuetz, Denise Daley, Stephen Leach, et al.
International Journal of Environmental Research and Public Health|March 19, 2020
Resources-Stratified Guidelines for Classical Hodgkin LymphomaAllan Relecom, Massimo Federico, Joseph M Connors, et al.
Blood Advances|December 6, 2019
Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarrayDiego Villa, King L Tan, Christian Steidl, et al.
Leukemia & Lymphoma|June 28, 2016
Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphomaAlden A Moccia, Felicitas Hitz, Paul Hoskins, et al.
Cancer Causes & Control : CCC|October 13, 2009
Interaction between organochlorines and the AHR gene, and risk of non-Hodgkin lymphomaCarmen H Ng, Rozmin Janoo-Gilani, Payal Sipahimalani, et al.
American Journal of Hematology|August 12, 2015
Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphomaTarec Christoffer El-Galaly, Diego Villa, Musa Alzahrani, et al.
International Journal of Cancer|November 12, 2009
GBV-C/hepatitis G virus infection and non-Hodgkin lymphoma: a case control studyMel Krajden, Amanda Yu, Heather Braybrook, et al.
Blood|October 5, 2017
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphomaBarbara Pro, Ranjana Advani, Pauline Brice, et al.
Blood|March 6, 2013
Analysis of FOXO1 mutations in diffuse large B-cell lymphomaDiane L Trinh, David W Scott, Ryan D Morin, et al.
Oncotarget|November 8, 2012
Recurrent targets of aberrant somatic hypermutation in lymphomaAlireza Hadj Khodabakhshi, Ryan D Morin, Anthony P Fejes, et al.
Pageof 31

Showing results (161-170 of 302) with videos related to

Sort By:
Pageof 31
Plos One|October 8, 2013
Non-Hodgkin lymphoma risk and variants in genes controlling lymphocyte developmentJohanna M Schuetz, Denise Daley, Stephen Leach, et al.
International Journal of Environmental Research and Public Health|March 19, 2020
Resources-Stratified Guidelines for Classical Hodgkin LymphomaAllan Relecom, Massimo Federico, Joseph M Connors, et al.
Blood Advances|December 6, 2019
Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarrayDiego Villa, King L Tan, Christian Steidl, et al.
Leukemia & Lymphoma|June 28, 2016
Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphomaAlden A Moccia, Felicitas Hitz, Paul Hoskins, et al.
Cancer Causes & Control : CCC|October 13, 2009
Interaction between organochlorines and the AHR gene, and risk of non-Hodgkin lymphomaCarmen H Ng, Rozmin Janoo-Gilani, Payal Sipahimalani, et al.
American Journal of Hematology|August 12, 2015
Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphomaTarec Christoffer El-Galaly, Diego Villa, Musa Alzahrani, et al.
International Journal of Cancer|November 12, 2009
GBV-C/hepatitis G virus infection and non-Hodgkin lymphoma: a case control studyMel Krajden, Amanda Yu, Heather Braybrook, et al.
Blood|October 5, 2017
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphomaBarbara Pro, Ranjana Advani, Pauline Brice, et al.
Blood|March 6, 2013
Analysis of FOXO1 mutations in diffuse large B-cell lymphomaDiane L Trinh, David W Scott, Ryan D Morin, et al.
Oncotarget|November 8, 2012
Recurrent targets of aberrant somatic hypermutation in lymphomaAlireza Hadj Khodabakhshi, Ryan D Morin, Anthony P Fejes, et al.
Pageof 31